News

EMA Post Authorisation Guidance Faces Evidence Gaps After 10 Years

EMA · 4 min

EMA approves TX01 PIP, unlocking the PUMA pathway for Theranexus and Exeltis

EMA · 5 min

CHMP backs nerandomilast for IPF and PPF in EU

European Medicines Agency · idiopathic pulmonary fibrosis · 6 min

KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)

3 min

EU secures emergency Favipiravir deliveries for hantavirus response

European Commission · hantavirus · 6 min

Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses

FDA · dry eyes · 5 min

Lightproof pharma packaging: ICH Q1B realities

EMA · 4 min

EMEA 2026 life sciences: UK equity and FDI shifts

4 min

Maersk Europe Market Update June 2026: Key Changes for Pharma Supply Chains

4 min

Regulatory round-up: 2 February 2026 – EMA opinions, FDA approvals, and what they mean for pharma

FDA · 4 min

The Baker Company Benelux BV joins EuropaBio: Advancing cell culture and lab safety technologies

4 min

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates

myasthenia gravis · 4 min